GSK
998 hedge funds and large institutions have $19.5B invested in GSK in 2025 Q4 according to their latest regulatory filings, with 181 funds opening new positions, 309 increasing their positions, 337 reducing their positions, and 63 closing their positions.
187% more first-time investments, than exits
New positions opened: 181 | Existing positions closed: 63
110% more call options, than puts
Call options by funds: $258M | Put options by funds: $123M
17% more capital invested
Capital invested by funds: $16.7B → $19.5B (+$2.85B)
11% more funds holding
Funds holding: 897 → 998 (+101)
0.55% more ownership
Funds ownership: 19.17% → 19.72% (+0.55%)
8% less repeat investments, than reductions
Existing positions increased: 309 | Existing positions reduced: 337
15% less funds holding in top 10
Funds holding in top 10: 13 → 11 (-2)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Wellington Management Group
Boston,
Massachusetts
|
+$426M |
| 2 |
Acadian Asset Management
Boston,
Massachusetts
|
+$288M |
| 3 |
Arrowstreet Capital
Boston,
Massachusetts
|
+$106M |
| 4 |
UBS Group
Zurich,
Switzerland
|
+$76.3M |
| 5 |
Point72 Asset Management
Stamford,
Connecticut
|
+$68.8M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Dodge & Cox
San Francisco,
California
|
-$461M |
| 2 |
Capital Research Global Investors
Los Angeles,
California
|
-$77.4M |
| 3 |
Balyasny Asset Management
Chicago,
Illinois
|
-$62.9M |
| 4 |
CCM
Causeway Capital Management
Los Angeles,
California
|
-$53.3M |
| 5 |
Renaissance Technologies
New York
|
-$44.4M |
GSK Hedge Fund Activity: Q4 2025 in Review
998 of the 8,284 institutional investors tracked by Wall St. Rank reported a position in GSK (GSK) for Q4 2025, worth a combined $19.5B — up 17% from $16.7B a quarter earlier.
Buyers outnumbered sellers: 181 funds opened new GSK positions and 63 closed out — a net gain of 118 holders — while 309 added to existing stakes and 337 trimmed.
The largest buyer was Wellington Management Group, adding an estimated $426M. The largest seller was Dodge & Cox, cutting an estimated $461M.
- 998 institutional investors held GSK (GSK) as of Q4 2025, up from 897 in Q3 2025.
- Funds reported $19.5B of GSK stock for Q4 2025, up 17% quarter-over-quarter.
- 181 funds opened new GSK positions in Q4 2025 and 63 closed out, a net change of +118 holders.
- The largest GSK buyer in Q4 2025 was Wellington Management Group, an estimated $426M added.
- The largest GSK seller in Q4 2025 was Dodge & Cox, an estimated $461M sold.
Based on aggregated 13F filings for Q4 2025.